Venus Remedies, AdjuTec Unite to Tackle Antimicrobial Resistance

A research collaboration agreement has been signed between Panchkula-based Venus Remedies Limited and AdjuTec Pharma AS, a Norwegian firm that is creating antibiotic resistance breakers. AdjuTec Pharma's APC-148 platform technology will undergo a pre-clinical study by Venus Remedies Limited.

AdjuTec Pharma has created innovative inhibitor technologies that restore the efficacy of commercially available antibiotics by specifically destroying the processes underlying antibiotic resistance in bacteria that are resistant to several drugs. The flagship program, APC-148, is currently undergoing phase 1 clinical trials.

Venus Remedies Limited, a leader in antimicrobial resistance (AMR) research, will use its sophisticated R&D resources to evaluate APC-148's ability to restore antibiotics' efficacy against bacterial strains that are resistant to several drugs.

Venus Remedies Limited will test APC-148 in combination with other antibiotics against its vast library of clinical isolates gathered from the GASAR investigation as part of this collaboration. The study is a component of Venus Remedies' larger effort to fight AMR and support the UN's "One Health" goal.

AdjuTec Pharma and Venus Remedies Limited are working together to combat the threat of AMR to world health. AMR is directly responsible for 1.3 million deaths worldwide each year, and by 2050, it is expected to have contributed to 39 million fatalities worldwide. AMR may overtake cancer as the primary cause of death if untreated.

With AMR prevalent and linked to over 300,000 fatalities in 2019 alone, including among infants, the situation is particularly dire in India. Antibiotic efficacy against resistant bacterial strains that are posing a growing threat to the Indian healthcare system could be considerably restored by APC-148.